Dual blockade of EGFR and VEGF-VEGFR signaling represents a promising therapeutic strategy in the treatment of EGFR mutant NSCLC patients with oligoprogressive disease given extensive crosstalk between these pathways in oncoangiogenesis and drug resistance (Zhou et al., 2025; Choi et al., 2022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.